Differential Second Primary Malignancy Occurrence After Breast Cancer According to HER2 Status: A Population-Based Study

Lin, Xiaojuan; Lin, Xiao; Li, Yingzi; Zhang, Yuchen; Lin, Jiali; Zhang, Guochun

doi:10.2147/ijgm.s338455

Cited by 1 publication

(1 citation statement)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surgery, chemotherapy, and targeted therapy are all effective treatments for the breast cancer patients. Targeted therapy is a successful treatment, especially for growth factor receptor 2 positive (HER2+) breast cancer, other targets were also found consciously [5][6][7][8].…”

Section: Introductionmentioning

confidence: 99%

ALKBH family members as novel biomarkers and prognostic factors in human breast cancer

Chen

Zhou

et al. 2022

Aging

View full text Add to dashboard Cite

Breast cancer is the most common lethal carcinoma worldwide and better targeted therapies are still worthy of exploration, having had some great successes already. Abnormal expression of ALKBH members were found in various cancers, and the roles played by it were the focus of attention. The ALKBH gene family encodes nine homologous enzymes (ALKBH1-8 and FTO) to repair DNA or RNA depending on Fe2+ and α-ketoglutarate (α-KG), which is related to carcinogenesis. In this study, we applied several databases to explore the roles of ALKBHs in breast cancer. We found that ALKBH members were abnormal expression in breast cancer and associated with tumor stage and subclasses. Higher alteration rates of ALKBH family were found in breast cancer. Function enrichment revealed that several cancer-associated signal pathways were related to ALKBH family such as PI3K-Akt signaling pathway and axon guidance. Infiltration of immune cells (Eosinophiles, NK CD56bright cells, mast cells, T helper cells and so on) were strongly related to ALKBHs. Moreover, we further found that there was strong correlation between ALKBH7 and higher age, later T stage, ER/PR positive and post-menopause of breast cancer patients, and patients with higher ALKBH7 expression had shorter overall survival (OS) and post progression survival (PPS). In conclusion, our findings may provide novel insights into ALKBH-targeted therapy for breast cancer patients, and ALKBH7 may be a potential prognostic biomarker.

show abstract

Section: Introductionmentioning

confidence: 99%